Abstract:Obesity can lead to excessive lipid accumulation in non-adipose tissues, such as the liver and skeletal muscles, leading to ectopic lipid deposition and damaging target organ function through lipotoxicity. FGF-21 is a key factor in regulating lipid metabolism, so we aim to explore whether FGF-21 is involved in improving ectopic lipid deposition. We observed the characteristics of ectopic lipid deposition in the liver and skeletal muscles of obesity-resistant mice, detected the expression of FGF-21 and perilipin, and found that obesity-resistant mice showed a decrease in ectopic lipid deposition in the liver and skeletal muscles and increased expression of FGF-21. After inhibiting the expression of FGF-21, a more severe lipid deposition in liver cells and skeletal muscle cells was found. The results indicate that inhibiting FGF-21 can exacerbate ectopic lipid deposition via regulating lipid droplet synthesis and decomposition, as well as free fatty acid translocation and oxidation. In conclusion, FGF-21 is involved in improving ectopic lipid deposition caused by obesity in the liver and skeletal muscles.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of fibroblast growth factor 21 (FGF - 21) in improving ectopic lipid deposition in the liver and skeletal muscle caused by obesity. Specifically, by observing the characteristics of ectopic lipid deposition in the liver and skeletal muscle of high - fat - diet - induced obesity - resistant mice (DIO - R), the researchers detected the expression changes of FGF - 21 and perilipin, and further verified the influence of FGF - 21 on lipid - metabolism - related proteins through in vitro experiments, in order to reveal the specific mechanism of FGF - 21 in regulating ectopic lipid deposition. ### Main research questions: 1. **Characteristics of ectopic lipid deposition**: Study the differences in ectopic lipid deposition in the liver and skeletal muscle between obesity - resistant mice (DIO - R) and ordinary obese mice (DIO). 2. **Expression changes of FGF - 21**: Explore the expression changes of FGF - 21 in obesity - resistant mice and its impact on ectopic lipid deposition. 3. **Changes of lipid droplet proteins**: Analyze the expression changes of PLIN2 and PLIN5 in different groups and their roles in regulating lipid deposition. 4. **Expression of lipid - metabolism - related proteins**: Study the expression changes of FAT/CD36 and CPT - 1 in high - fat - induced cell models and the roles of these proteins in lipid metabolism. ### Research background: - **Ectopic lipid deposition**: Excessive fat accumulates in non - adipose tissues (such as the liver and skeletal muscle), leading to lipotoxicity and impairing the function of target organs. - **Role of FGF - 21**: FGF - 21 is an important metabolic regulator, participating in fatty acid oxidation and ketogenesis and inhibiting adipogenesis. ### Research methods: - **Animal models**: Use C57BL/6J mice, divided into normal control group (NC), high - fat - diet - induced obesity group (DIO), and high - fat - diet - induced obesity - resistant group (DIO - R). - **Tissue sampling**: Collect liver and skeletal muscle tissues, perform HE staining and Oil Red O staining to detect lipid deposition. - **Cell culture and transfection**: Use HepG2 and C2C12 cells to establish high - fat - induced cell models, inhibit the expression of FGF - 21 by siRNA, and detect the expression changes of related proteins. ### Main findings: - **Obesity - resistant mice**: The body weight, white adipose tissue (WAT) and brown adipose tissue (BAT) weights of mice in the DIO - R group were all lower than those in the DIO group, and the serum free fatty acid (FFA) content was also significantly reduced. - **Reduced ectopic lipid deposition**: The lipid deposition in the liver and skeletal muscle of mice in the DIO - R group was significantly reduced, the ratio of liver wet weight to body weight increased, but the TG content decreased. - **Increased FGF - 21 expression**: The expression of FGF - 21 in the liver and skeletal muscle of mice in the DIO - R group was significantly increased. - **Changes of lipid droplet proteins**: In the liver of mice in the DIO - R group, the expression of PLIN2 decreased, while the expression of PLIN5 increased; in the skeletal muscle, the expression of PLIN2 increased and the expression of PLIN5 also increased. - **Lipid - metabolism - related proteins**: In the high - fat - induced cell model, the expressions of FAT/CD36 and CPT - 1 increased, and after inhibiting FGF - 21, lipid deposition was aggravated. ### Conclusion: FGF - 21 plays an important role in improving ectopic lipid deposition in the liver and skeletal muscle caused by obesity. By regulating lipid droplet synthesis and decomposition, free fatty acid transport and oxidation, it reduces lipotoxicity. This finding provides a theoretical basis for improving abnormal lipid metabolism in the future.

Increased FGF-21 Improves Ectopic Lipid Deposition in the Liver and Skeletal Muscle

Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice

Fibroblast Growth Factor 21 is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response and Counteracts Endoplasmic Reticulum Stress-Induced Hepatic Steatosis.

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

Fibroblast Growth Factor 21 Suppresses Adipogenesis in Pig Intramuscular Fat Cells

Fibroblast Growth Factor 21 Increases Insulin Sensitivity Through Specific Expansion of Subcutaneous Fat

FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk

Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A

FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation

Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease

FGF21: A Sharp Weapon in the Process of Exercise to Improve NAFLD

Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism.

Insulin-like Growth Factor Binding Protein 1 Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease

FGF21 in obesity and cancer: New insights

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

Hepatic-Specific FGF21 Knockout Abrogates Ovariectomy-Induced Obesity by Reversing Corticosterone Production

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

[Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease].

Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice

Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis

Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge